BOSTON , Nov. 12, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that it has entered into definitive securities purchase agreements for the sale of its common stock and warrants to purchase common stock in a private placement that is expected to result in gross
BOSTON , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP), today announced that it has rescheduled its quarterly conference call to Monday, Nov. 12 , at 8 a.m. ET to provide a corporate update and discuss financial results for the third quarter ended Sept.
BOSTON , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper , M.D., Ph.D., Chief Executive Officer, will present at the Stifel 2018 Healthcare Conference in New York on Wednesday, Nov. 14 , at 1:15 p.m. ET .
BOSTON , Nov. 05, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP), a biotechnology company focused on development of next generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer, today announced it will update data from its Phase 1 trial of
BOSTON , Oct. 31, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP), today announced that management will host a conference call and webcast slide presentation on Thursday, Nov. 8 , at 4:30 p.m. ET to provide a corporate update and discuss financial results for the third quarter ended
-- CEO Laurence Cooper Appointed to Board of Directors -- Francois Lebel to Depart Company BOSTON , Oct. 16, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP), a biotechnology company focused on development of next generation immunotherapies utilizing gene- and cell-based therapies
Ziopharm to Host Conference Call at 8 a.m. BOSTON and GERMANTOWN, Md., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP) and Precigen, Inc. , a wholly-owned subsidiary of Intrexon Corporation (Nasdaq: XON), today announced a new definitive license agreement to replace all
BOSTON , Sept. 25, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP), today announced that Laurence Cooper , M.D., Ph.D., Chief Executive Officer, will present at the Cantor Fitzgerald 2018 Global Healthcare Conference in New York on Tuesday, Oct. 2 , at 2:15 p.m. ET .
BOSTON , Sept. 04, 2018 (GLOBE NEWSWIRE) -- In a release issued earlier today by Ziopharm Oncology , Inc. (Nasdaq:ZIOP), please note the Company's upcoming annual meeting of stockholders is being held Sept. 18 rather than Sept. 8 as originally issued.
Company Focused on Responding to FDA for Third-generation Trial NCI to file IND for Sleeping Beauty Manufactured TCR-T Cell Therapies Targeting Neoantigens in 4Q2018 Controlled IL-12 Monotherapy, Combination Studies Advancing Changes to Board of Directors and New Staff Illustrate Company Growth
